Adipotide (Prohibitin-TP01)
Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity
On this page
What is Adipotide (Prohibitin-TP01)?
Adipotide is an experimental peptidomimetic — a lab-made compound that mimics peptide structure — designed to target the blood vessels supplying white fat tissue. Animal-model research in obese primates has studied its effects on fat-tissue vasculature and metabolic markers like insulin sensitivity, though a related human oncology trial raised kidney-safety concerns that halted further development. This is strictly an animal-model and in vitro research compound, not evaluated or approved for use in people.
Key terms:
Adipotide (Prohibitin-TP01) is a synthetic peptidomimetic.
Adipotide (Prohibitin-TP01) is a lab-made compound that mimics a peptide. It has two joined parts. One locks onto prohibitin and annexin A2, proteins on the blood vessels that feed white fat tissue. The other, a D-(KLAKLAK)2 motif, tells those vessel cells to self-destruct. In obese primates, researchers reported rapid fat reduction and improved insulin resistance. Development stopped after an early Phase 1 cancer trial. Kidney safety signals — reversible changes in the proximal tubule — remain a key concern.
Key research areas
- Rapid fat-mass reduction in obese non-human primates
- Improved insulin sensitivity
- Direct WAT vascular targeting
Researched dosing
This table reflects the dose-finding schedules used in primate research studies with adipotide — animal-model research methodology, never a personal dosing guide.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Primate-model replication | 0.43 mg/kg | Once daily | Subcutaneous |
| Dose-finding studies | 0.10-0.75 mg/kg | Once daily | Subcutaneous (escalating tiers) |
Commonly cycled 4 weeks on, 4+ weeks off.
How it works
At the cell level, adipotide research looks at how this experimental compound homes to specific markers on fat-tissue blood vessels and triggers localized cell death in that vasculature — animal-model research, not a description of what happens in a person.
CKGGRAKDC homes to prohibitin/annexin A2 on white-fat endothelium; the linked D-(KLAKLAK)2 disrupts mitochondrial membranes after internalization, triggering localized endothelial apoptosis and adipocyte loss.
Research applications
This section summarizes the animal-model research areas — fat-tissue vasculature and metabolic markers like insulin sensitivity — that scientists have studied for adipotide in primate models; it is not a claim about outcomes in people.
Weight Reduction
Selective WAT vascular targeting produced 7-15% body-weight reduction over 4 weeks in obese macaques through adipose endothelial apoptosis and adipocyte loss.
Metabolic
Improved insulin sensitivity accompanying fat mass reduction in primate models.
Appetite Control
Indirect appetite modulation through fat mass reduction and metabolic improvement.
Dosage reference
- Doses used in research
- Animal studies used 0.43 mg/kg (primate models); no established human-research dose.
- Frequency in studies
- Once daily
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Fat Reduction visible by 2-4 weeks in primate models
- Storage
- 2-8°C
- Cycle length
- 28 days
- Break between cycles
- ≥4 weeks
Interactions
This list shows which other metabolic-research compounds and drug classes have been studied alongside adipotide, and flags combinations noted for extra caution in a research setting.
Reconstitution & storage
This is the standard laboratory method for preparing a research solution of adipotide from powder — a chemistry-handling note for lab use.
- Sanitize hands and workspace; swab vial septum.
- Inject BAC water slowly down the vial wall; do not jet onto powder.
- Gently swirl until fully dissolved (do not shake).
- Label with concentration/date; store at 2-8°C; discard per lab SOP.
Lyophilized: 2-8°C, use within Per manufacturer expiration date
Reconstituted: 2-6°C, use within Per lab SOP
Open the Adipotide reconstitution calculatorQuality indicators
These are the visual checks researchers use to confirm an adipotide sample hasn't degraded before it goes into a study.
Intact Lyophilized Cake - White, uniform ‘cake’ indicates proper lyophilization.
Clear Solution - Fully dissolved, particle‑free solution after reconstitution.
Minor Clumping - Small clumps may form from shipping; should fully dissolve with gentle swirl.
Collapsed/Moist Cake - Suggests temperature excursion; do not use without QC.
Cloudiness/Precipitate - Indicates degradation or contamination—discard per SOP.
What to expect
This timeline reflects what animal-model research has reported at each stage of a study in primates — research context for comparing studies, not a personal-results promise or a claim about human outcomes.
Early reduction in abdominal circumference
Progressive weight/fat-mass decline
Safety notes
This section covers handling cautions and regulatory status for adipotide — it is not FDA-approved, remains investigational, and the entry flags a documented kidney-safety signal from primate research as a caution for laboratory handling, not medical guidance.
- Pregnancy/lactation: not studied; avoid
- Avoid dehydration; consider temporarily pausing if creatinine rises persistently
- Not FDA-approved; investigational/educational only.
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Molecular MRI using CKGGRAKDC confirmed prohibitin-based adipose targeting, supporting the translational targeting concept.
7.4-14.7% weight reduction; insulin resistance improved; mild, dose-dependent, reversible proximal tubule changes. White-adipose vasculature targeting led to rapid fat mass reduction and improved insulin dynamics.
Dose-dependent efficacy; renal safety signal >0.25 mg/kg. Identified 0.43 mg/kg SC daily as the optimal primate dose balancing efficacy and renal safety.